Rifaximin Treatment of Papulopustular Rosacea

• Status: Withdrawn
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• Males and females

• > 18 years of age with rosacea defined as:

• 3-40 papules/pustules and < 2 nodules,

• A score of 2-4 on the Investigator Global Assessment

Exclusion Criteria:

• Untreated pancreatic insufficiency

• Crohn's disease

• Ulcerative colitis

• Active celiac disease by clinical history

• End stage renal failure

• Less than 18 years old

• Pregnancy or positive pregnancy test

• Rosacea subtype 1 (no papules )

• Topical or oral antibiotics within 4 weeks

• Acne treatments within 4 weeks prior to randomization

• Systemic retinoids within 90 days

• Topical or systemic corticosteroids 4 weeks prior to randomization